Introducing Blind

October 3, 2010

Introducing Blind, a screen reader script search engine and podcast publisher. A glimpse into blind and visually impaired culture from their own work and in their own words. It has podcasts, and information that my break some myths you may have about blindness.

There is a little website that has been around for a few years. It is little known in relation to some you may have heard of like,,,, and so on. It may even be because it comes from a segment of the population that many actually know little about. It is the blind and visually impaired community. Many people are not aware that the blind have a community and culture that is both all their own, and also very similar to any other community. Many people are not even aware of the technology that allow blind people to operate a computer as well as, or in some cases even better than the sighted world. In fact, the entire website and its podcast content is created by the blind and visually impaired. The ultimate goal of Blind is to educate and raise awareness of not just blind people in general, but to also give you a glimpse into their culture and way of life. On the site you will discover things you may have never thought it possible for the blind to be capable of. In fact, even the website itself is coded and designed by John Greer who is also visually impaired. One of the more notable sections of the site are the podcasts and downloadable internet shows they produce. The shows cover many aspects of their culture and lifestyle. You will hear how blind people are able to cook, use computers, the political issues they have, the technology they use, and much more.

Blind Crawler is an informational site, a search engine for an assistive software called Jaws and also a podcast publisher. The service Blind Crawler provides is free for anyone to enjoy, but PayPal donations are also welcome.


Researchers find no difference in drugs for macular degeneration

October 2, 2010

Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to ranibizuamab. Last October, these same researchers published early, six month outcomes of the same study, which also failed to show a difference in efficacy between these two drugs for treating AMD.